Psyence BioMed invests $500,000 more into PsyLabs, locks down Ibogaine supply deal
The biotech firm expands its psychedelics pipeline with rights to a promising addiction treatment compound.
The post Psyence BioMed invests $500,000 more into PsyLabs, locks down Ibogaine supply deal appeared first on Green Market Report.
